PHASE I - II TRIAL OF A 5 - DAY CONTINUOUS INFUSION OF VINBLASTINE SULFATE
- 1 January 1984
- journal article
- research article
- Vol. 4 (6) , 411-414
Abstract
Vinblastine sulfate was administered to 28 patients as a continuous infusion for 5 consecutive days in doses of 0.75-2.0 mg/m2. Pharmacokinetic studies in 4 patients showed that plasma levels increased rapidly after beginning of the infusion, with a steady state occurring in 10-48 h at 2 ng/ml for 1.25 mg/m2, and 5-8 ng/ml for 2.0 mg/m2. The T1/2 b after completion of the infusion was 19 h. Dose-limiting toxicity was myelosuppression. A partial remission of 4 mo. duration was observed in a patient with adenocarcinoma of the gastroesophageal junction. One patient, who had been heavily pretreated, obtained partial remission, 3 patients with breast cancer had a minor response. There was no response in 10 patients with hypernephroma. The suggested starting dose is 2 mg/m2 for unpretreated cases and 1.75 mg/m2 daily for 5 consecutive days monthly for prior treated cases.This publication has 4 references indexed in Scilit:
- VINBLASTINE GIVEN AS A CONTINUOUS 5-DAY INFUSION IN THE TREATMENT OF REFRACTORY ADVANCED BREAST-CANCER1980
- SINGLE-AGENT THERAPY FOR RENAL CELL-CARCINOMA - CCNU, VINBLASTINE, THIOTEPA, OR BLEOMYCIN1977
- VINCA ALKALOIDS - A NEW CLASS OF ONCOLYTIC AGENTS1963
- TREATMENT OF MALIGNANT CEREBRAL ASTROCYTOMAS BY INTRA-ARTERIAL INFUSION OF VINBLASTINE1962